This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in the treatment of BCL2/MYC protein double expressor lymphoma.
Each potential subject must satisfy all of the following criteria to be enrolled in the study.
Any potential subject who meets any of the following criteria will be excluded from participating in the study.
Patients with accessible tissue samples were selected from a phase III study of tucidinostat in combination with R-CHOP in patients with newly diagnosed double expressor DLBCL (NCT04231448).
Cohort
Retrospective
Not listed
Event Free Survival (EFS)
Defined as the duration from the date of randomization to the date of disease progression, relapse from CR , initiation of subsequent systemic antilymphoma therapy for residual disease, or death, whichever occurs first.
Progression-Free Survival (PFS)
Defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
